Payment overview · 2025
General Payments
$2,506.41
129 reported records · 16 companies
Healthcare provider profile · identity verified
Troy Pulas, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · NEW PORT RICHEY, FL · NPI 1407074263
Verified facts
What the public records show
CMS Open Payments records show Troy Pulas, M.D. received $2,506.41 in general payments during 2025 across 129 reported records.
Vanda Pharmaceuticals Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Fanapt, Ingrezza, Quviviq, Spravato.
IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Quviviq by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 611 claims for Spravato by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 586 records involving 456 distinct recipient NPIs. Public Medicare Part D data also shows 611 claims for Spravato by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ingrezza by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Austedo Xr by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $459.03 | 18.3% | 20 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $344.96 | 13.8% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $315.63 | 12.6% | 24 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $219.63 | 8.8% | 14 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $217.73 | 8.7% | 15 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $200.00 | 8.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $166.84 | 6.7% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $157.77 | 6.3% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $105.68 | 4.2% | 6 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $70.84 | 2.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54.85 | 2.2% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $52.54 | 2.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.53 | 2.1% | 2 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $37.44 | 1.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.04 | 1.4% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $16.90 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,306.41 | 128 |
| Consulting Fee | $200.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $459.03 | 20 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $350.99 | 15 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $344.96 | 16 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $315.63 | 24 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC | $309.22 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $229.19 | 14 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $184.37 | 13 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $184.37 | 13 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $157.77 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $72.30 | 4 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $70.84 | 3 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $57.62 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $54.85 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $52.54 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $42.97 | 2 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $33.38 | 2 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Quviviq quviviq |
2025 | Quviviq | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SPRAVATO spravato |
2025 | Spravato | 2024 | 611 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference |
2025 | QUVIVIQ open payments reported associated product |
CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023 |
Quviviq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
611 | 30 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 586 supporting records · 456 recipient NPIs · example record 1174147619 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
611 | 30 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Spravato | Esketamine Hcl | 611 | 30 |
| Alprazolam | Alprazolam | 510 | 94 |
| Clonazepam | Clonazepam | 435 | 81 |
| Trazodone Hcl | Trazodone Hcl | 374 | 111 |
| Buspirone Hcl | Buspirone Hcl | 367 | 111 |
| Lamotrigine | Lamotrigine | 333 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 244 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 212 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 207 | 51 |
| Lorazepam | Lorazepam | 199 | 37 |
| Sertraline Hcl | Sertraline Hcl | 178 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 178 | 43 |
| Bupropion Xl | Bupropion Hcl | 174 | 52 |
| Mirtazapine | Mirtazapine | 166 | 49 |
| Aripiprazole | Aripiprazole | 160 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 49 |
| Gabapentin | Gabapentin | 121 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 119 | 34 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 113 | 30 |
| Olanzapine | Olanzapine | 110 | 25 |
| Diazepam | Diazepam | 105 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 99 | 23 |
| Oxcarbazepine | Oxcarbazepine | 96 | 28 |
| Propranolol Hcl | Propranolol Hcl | 95 | 26 |
| Risperidone | Risperidone | 82 | 17 |
| Prazosin Hcl | Prazosin Hcl | 74 | 20 |
| Divalproex Sodium | Divalproex Sodium | 69 | 14 |
| Temazepam | Temazepam | 69 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 68 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 67 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 52 | 17 |
| Lurasidone Hcl | Lurasidone Hcl | 50 | 14 |
| Vraylar | Cariprazine Hcl | 44 | suppressed |
| Clozapine | Clozapine | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 13 |
| Ziprasidone Hcl | Ziprasidone Hcl | 36 | suppressed |
| Paliperidone Er | Paliperidone | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 31 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Ingrezza | Valbenazine Tosylate | 28 | suppressed |
| Austedo Xr | Deutetrabenazine | 25 | suppressed |
| Belsomra | Suvorexant | 25 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 19 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Perphenazine | Perphenazine | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 14 | suppressed |
| Fanapt | Iloperidone | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Metformin Hcl | Metformin Hcl | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Quviviq | Daridorexant Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,506.41 · 129 records | Vanda Pharmaceuticals Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, BRIXADI, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, LOREEV XR, LYBALVI, Qelbree, Quviviq, REXULTI, SPRAVATO, SUBLOCADE, UZEDY, VIVITROL | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with IDORSIA PHARMACEUTICALS US INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error